S&P: Valeant unaffected

Standard & Poor's said that Valeant Pharmaceuticals International's (B+/stable) announcement that it intends to repurchase $200 million of its shares over the next two years does not have an impact on the current rating or outlook.

Valeant had nearly $364 million in cash on-hand as of March 31, the agency said, and is expected to continue to generate positive free cash flow from its diverse pharmaceutical product portfolio.

Debt to EBITDA of 3.7x is also in line with the current rating, S&P said.

However, S&P said it is somewhat concerned that this share repurchase will diminish the company's flexibility to conduct product acquisitions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.